European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Vaccines matter for each of us: yearly, they prevent 2.7 million people from contracting measles, one million from getting whooping cough and two million babies from getting tetanus. They eradicated smallpox. They stopped polio, a dreadful disease affecting millions of children, in almost all... more

Field of Interest: European Union Medical News
Type: News Feed

Human medicines European public assessment report (EPAR): Vyepti, eptinezumab, Date of authorisation: 24/01/2022, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR): Vyepti, eptinezumab, Date of authorisation: 24/01/2022, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR): Kyinsu, insulin icodec,semaglutide, Date of authorisation: 24/11/2025, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Kyinsu, insulin icodec,semaglutide, Date of authorisation: 24/11/2025, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Padcev, enfortumab vedotin, Date of authorisation: 13/04/2022, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Padcev, enfortumab vedotin, Date of authorisation: 13/04/2022, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Kisunla, donanemab, Date of authorisation: 24/09/2025, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Kisunla, donanemab, Date of authorisation: 24/09/2025, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Leflunomide ratiopharm, leflunomide, Date of authorisation: 28/11/2010, Revision: 22, Status: Authorised

Human medicines European public assessment report (EPAR): Leflunomide ratiopharm, leflunomide, Date of authorisation: 28/11/2010, Revision: 22, Status: Authorised

Human medicines European public assessment report (EPAR): mResvia, respiratory syncytial virus mRNA vaccine, Date of authorisation: 22/08/2024, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): mResvia, respiratory syncytial virus mRNA vaccine, Date of authorisation: 22/08/2024, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Soliris, eculizumab, Date of authorisation: 20/06/2007, Revision: 42, Status: Authorised

Human medicines European public assessment report (EPAR): Soliris, eculizumab, Date of authorisation: 20/06/2007, Revision: 42, Status: Authorised

Human medicines European public assessment report (EPAR): Clopidogrel Viatris (previously Clopidogrel Taw Pharma), clopidogrel, Date of authorisation: 16/10/2009, Revision: 30, Status: Authorised

Human medicines European public assessment report (EPAR): Clopidogrel Viatris (previously Clopidogrel Taw Pharma), clopidogrel, Date of authorisation: 16/10/2009, Revision: 30, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness